Autopsy report · NCT04986865

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

“It is due to the recent changes in the competitor landscape and strategic consideration”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 3 years 2 months before it stopped.
• 31 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Antengene Biologics Limited

Sponsor type

Industry

Conditions

Advanced Solid Tumor; Metastatic Solid Tumor; Mature B-cell Non-Hodgkin Lymphoma

Interventions

ATG-101

Participants

31

Sites

8

Countries

Australia, United States

Trials that died the same way

• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (66% match in meaning)
• Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
  “Due to corporate strategic adjustment.” (65% match in meaning)
• Safety and Efficacy of Periodontal Surgery in Supra-alveolar-type Defects With or Without Straumann® Emdogain
  “Due to change in strategy and decision not to expand indication.” (61% match in meaning)
• Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
  “Due to development strategy change.” (60% match in meaning)
• IBI397 or Combination Therapies in Patients With Advanced Malignancies
  “Due to the company's development strategy adjustment” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.